Human papillomavirus types 6, 11, 16, 18 (HPV-6/11/16/18)

Human papillomavirus (HPV) types 6, 11, 16, and 18 are double-stranded DNA viruses that specifically infect the basal layer of cutaneous and mucosal epithelium (CDC, 2021). Types 16 and 18 are classified as high-risk genotypes and are responsible for approximately 70% of cervical cancers globally, as well as a significant proportion of anal, vulvar, and oropharyngeal malignancies (WHO, 2023). These high-risk types drive oncogenesis primarily through the expression of E6 and E7 oncoproteins, which degrade the host tumor suppressors p53 and pRb, respectively (NCI, 2023). Conversely, types 6 and 11 are low-risk genotypes that cause roughly 90% of anogenital warts and are the primary agents in recurrent respiratory papillomatosis (StatPearls, 2023). These four types are the specific targets of the quadrivalent HPV vaccine, which utilizes recombinant L1 capsid proteins to form virus-like particles (VLPs) that induce a robust humoral immune response (PubMed, 2017). The resulting neutralizing antibodies prevent the virus from entering host cells, thereby providing high levels of protection against both benign and malignant disease progression associated with these genotypes.

Other names

HPV 6HPV 11HPV 16HPV 18Human papillomavirus 6Human papillomavirus 11Human papillomavirus 16Human papillomavirus 18Quadrivalent Human Papillomavirus

Prophylactic vaccines utilize recombinant L1 capsid proteins to form virus-like particles (VLPs) that induce neutralizing antibodies, preventing viral attachment and entry into host basal epithelial cells (NCI, 2023). Topical therapeutic agents like imiquimod act as toll-like receptor 7 (TLR7) agonists to stimulate a local innate and cell-mediated immune response against the virus (StatPearls, 2023).